In this context, TGFβ signaling by intestinal DCs [57] and circulating monocytes [58] exerts an anti-inflammatory effect, and therapeutically augmenting this pathway shows therapeutic benefits in CD patient clinical trials [59]. Here, TGFB1 is linked to Cowden disease.